Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03826875 · ClinicalTrials.gov registry record · Phase 2
Poststroke Depression in Hemorrhagic Stroke
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03826875 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 8 participants.
The verdict
NCT03826875, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
A double-blinded placebo-controlled randomized trial to evaluate the effect of preventative treatment of depression in survivors of aneurysmal subarachnoid hemorrhage (aSAH), a type of stroke.
Interventions
- DRUG Placebo
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2025-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03826875
The ClinicalTrials.gov registry entry for NCT03826875 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03826875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03826875 about?
NCT03826875 is a clinical study titled "Poststroke Depression in Hemorrhagic Stroke". A double-blinded placebo-controlled randomized trial to evaluate the effect of preventative treatment of depression in survivors of aneurysmal subarachnoid hemorrhage (aSAH), a type of stroke.
What is the current status of trial NCT03826875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2019-03-01. Estimated completion is 2025-05-07.
What interventions are being tested in trial NCT03826875?
The interventions under investigation include: Placebo (DRUG), Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT03826875?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.